Home/Pipeline/Reldesemtiv

Reldesemtiv

Amyotrophic Lateral Sclerosis (ALS)

Phase 3Completed (COURAGE-ALS)NCT

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 3

Status

Completed (COURAGE-ALS)

Company

Cytokinetics

About Cytokinetics

Cytokinetics' mission is to develop innovative medicines that improve the healthspan of patients suffering from cardiovascular and neuromuscular diseases characterized by compromised muscle function. Its key achievement is the 2025 FDA approval of MYQORZO (aficamten), a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), validating its decades-long focus on sarcomere biology. The company's strategy is to build a leading muscle-focused specialty biopharma business by commercializing aficamten across HCM subtypes, advancing late-stage candidates in heart failure, and leveraging its platform to develop treatments for neuromuscular conditions like ALS.

View full company profile

Therapeutic Areas

Cardiovascular Neuromuscular

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active